Wedbush Research Analysts Cut Earnings Estimates for TVTX

Travere Therapeutics, Inc. (NASDAQ:TVTX) – Wedbush decreased their Q1 2025 earnings per share (EPS) estimates for shares of Travere Therapeutics in a research note issued to investors on Monday, February 24th. Wedbush analyst L. Chico now forecasts that the company will post earnings per share of ($0.43) for the quarter, down from their previous forecast of ($0.42). The consensus estimate for Travere Therapeutics’ current full-year earnings is ($1.40) per share. Wedbush also issued estimates for Travere Therapeutics’ Q2 2025 earnings at ($0.19) EPS, Q3 2025 earnings at ($0.07) EPS and FY2025 earnings at ($0.56) EPS.

TVTX has been the subject of several other reports. JPMorgan Chase & Co. increased their price objective on Travere Therapeutics from $42.00 to $44.00 and gave the stock an “overweight” rating in a report on Wednesday. HC Wainwright raised their price target on Travere Therapeutics from $18.00 to $22.00 and gave the company a “buy” rating in a research report on Wednesday, January 15th. Scotiabank raised their price target on Travere Therapeutics from $27.00 to $32.00 and gave the company a “sector outperform” rating in a research report on Wednesday, February 12th. Evercore ISI lifted their target price on Travere Therapeutics from $33.00 to $45.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 12th. Finally, Canaccord Genuity Group lifted their target price on Travere Therapeutics from $22.00 to $45.00 and gave the stock a “buy” rating in a research report on Wednesday, February 12th. One analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $30.62.

Travere Therapeutics Price Performance

Shares of NASDAQ:TVTX opened at $21.40 on Thursday. The company has a current ratio of 1.71, a quick ratio of 1.68 and a debt-to-equity ratio of 24.96. Travere Therapeutics has a 1 year low of $5.12 and a 1 year high of $25.29. The business has a fifty day simple moving average of $20.05 and a 200 day simple moving average of $17.00. The firm has a market cap of $1.67 billion, a price-to-earnings ratio of -5.22 and a beta of 0.72.

Travere Therapeutics (NASDAQ:TVTX) last released its earnings results on Thursday, February 20th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.15). The business had revenue of $74.79 million during the quarter, compared to analysts’ expectations of $72.38 million. Travere Therapeutics had a negative net margin of 137.90% and a negative return on equity of 1,636.87%.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of TVTX. GF Fund Management CO. LTD. acquired a new stake in shares of Travere Therapeutics during the 4th quarter worth approximately $31,000. Sterling Capital Management LLC raised its stake in shares of Travere Therapeutics by 859.8% during the fourth quarter. Sterling Capital Management LLC now owns 2,361 shares of the company’s stock valued at $41,000 after acquiring an additional 2,115 shares during the last quarter. R Squared Ltd bought a new position in shares of Travere Therapeutics during the fourth quarter valued at $53,000. Gen Wealth Partners Inc bought a new position in Travere Therapeutics during the fourth quarter worth $73,000. Finally, Quarry LP bought a new position in Travere Therapeutics during the third quarter worth $105,000.

Insider Buying and Selling

In other news, SVP William E. Rote sold 2,437 shares of the company’s stock in a transaction dated Wednesday, January 22nd. The shares were sold at an average price of $19.46, for a total value of $47,424.02. Following the sale, the senior vice president now directly owns 83,170 shares of the company’s stock, valued at approximately $1,618,488.20. This represents a 2.85 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Sandra Calvin sold 15,000 shares of the company’s stock in a transaction dated Thursday, December 26th. The shares were sold at an average price of $17.22, for a total transaction of $258,300.00. Following the completion of the transaction, the chief accounting officer now owns 54,927 shares in the company, valued at approximately $945,842.94. This trade represents a 21.45 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 206,335 shares of company stock valued at $4,453,012. Company insiders own 4.06% of the company’s stock.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.